文献速递免疫规划传染病防控与疫情报告

美国与韩国不良事件报告系统中流感减毒活疫苗接种后吉兰-巴雷综合征的信号与趋势

Signals and trends of Guillain-Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems.
PubMed 文献 · Vaccine · 2020-06-27

本研究基于美国VAERS(400,535份)与韩国KAERS(28,766份)2005—2017年不良事件报告,采用病例/非病例的不比例分析评估流感疫苗接种与吉兰-巴雷综合征(GBS)的关联。两库中GBS均为流感免疫后最常报告的AE,VAERS调整ROR为3.57(95%CI 3.16-4.03),KAERS为3.09(95%CI 0.83-11.45);接种减毒活疫苗者GBS报告为其他疫苗类型的2.30倍(95%CI 1.74-3.05)。作者认为需谨慎监测流感疫苗接种后GBS,尤其减毒活疫苗,但因新疫苗AEFI报告有限存在报告偏倚,尚需前瞻性安全性研究。

要点

  • 两库中GBS均为流感免疫后最常报告的不良事件
  • VAERS中GBS调整ROR为3.57(95%CI 3.16-4.03)
  • 减毒活疫苗者GBS报告为其他疫苗类型的2.30倍(95%CI 1.74-3.05)

核心结论

  • 美国与韩国AEFI报告系统分析提示应对流感疫苗接种后GBS保持谨慎监测,尤其是减毒活疫苗接种后。
  • 因新类型流感疫苗AEFI报告有限可能导致报告偏倚,仍需进一步前瞻性安全性研究。

研究设计与样本

  • 基于美国VAERS的400,535份与韩国KAERS的28,766份2005—2017年不良事件报告进行分析。
  • 采用病例/非病例(case/non-case)方法进行不比例分析,检测安全信号并评估流感疫苗接种与GBS的潜在风险。

主要发现

  • 两数据库中GBS均为流感免疫后最常报告的不良事件。
  • VAERS中GBS的调整ROR为3.57(95%CI 3.16-4.03),KAERS中为3.09(95%CI 0.83-11.45)。
  • 接种减毒活疫苗者报告的GBS病例为接种其他类型疫苗者的2.30倍(95%CI 1.74-3.05)。

临床怎么用

  • 在流感疫苗接种后的安全性监测中,应将GBS作为重点关注的神经系统不良事件。
  • 对减毒活流感疫苗接种人群可加强GBS相关信号监测,并结合报告偏倚谨慎解读ROR结果。

局限性

  • 新类型流感疫苗引入后的AEFI报告有限,可能导致报告偏倚。
  • 研究基于自发报告系统数据,需进一步开展前瞻性安全性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With the advent of live-attenuated, quadrivalent, and cell-cultured vaccines for influenza, there have been discussions on the safety of these vaccines compared to conventional vaccines (such as inactivated, trivalent, and egg-cultured vaccines) because of the development of neurological adverse events (AEs). This study aimed to compare the trends and safety signals in the AE reporting systems of the US and South Korea and, more particularly, to evaluate the association between influenza vaccination and Guillain-Barré syndrome (GBS). METHODS: In total, 400,535 AE reports from the US Vaccine Adverse Event Reporting System (VAERS) and 28,766 AE reports from the Korea Adverse Event Reporting System (KAERS) between 2005 and 2017 were assessed. Disproportionality analysis was performed to detect the safety signals and examine the potential risk of GBS with influenza vaccination using the case/non-case approach. RESULTS: In both databases, GBS was the most frequently reported AE following influenza immunization. Using the case/non-case approach, the adjusted reporting odds ratio (ROR) of GBS was 3.57 (95% confidence interval [CI], 3.16-4.03) and 3.09 (95% CI, 0.83-11.45) in the VAERS and KAERS data, respectively. People vaccinated with live-attenuated vaccines reported 2.30 times (95% CI, 1.74-3.05) more cases of GBS than those vaccinated with other types of vaccines. CONCLUSIONS: Our analysis of the VAERS and KAERS reports for AEs following immunization (AEFI) for influenza shows the need for cautious monitoring regarding the development of GBS after influenza vaccination, particularly, after live-attenuated vaccination. However, owing to potential reporting bias caused by limited AEFI reports after the introduction of new types of influenza vaccines, further prospective safety studies are needed.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lee H, Kim HJ, Choe YJ, et al. Signals and trends of Guillain-Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems. Vaccine. 2020. PMID: 32600907. doi:10.1016/j.vaccine.2020.06.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。